Definition

A preparation of T lymphocytes that has been genetically modified to express a T-cell receptor (TCR) specific for an as of yet not identified viral oncoprotein(s) of human papillomavirus type 16 (HPV16), with potential antineoplastic activity. Upon intravenous administration, the anti-HPV16 TCR-engineered T cells CRTE7A2-01 specifically recognize and bind to the HPV16 oncoprotein(s) expressed on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the HPV16 oncoprotein(s).